3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
17
Stomach Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Rectal Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Solid Tumor
2
Recurrence
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Resectable NSCLC
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Metastatic Gastroesophageal Junction Adenocarcinoma
1
Meningeal Carcinomatosis
1
MSI-H
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
sintilimab
×
1 year
×
Clear all
No trials found.